(Q59273877)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Umberto Vitolo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

ESMO Guidelines Working Group

12 March 2020

7

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

M Dreyling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Ghielmini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

R Marcus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Ladetto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

13 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

25 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

suppl 3

0 references

page(s)

iii76-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Marching single file or 2 abreast

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

First-line treatment of follicular lymphoma: a patient-oriented algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU200

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25122695%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference